Coherus Oncology Inc (CHRS) Q1 2026 Earnings Report

Coherus Oncology reported a Q1 2026 net loss driven by continued investment in growth initiatives and a deliberate strategic pivot away from biosimilar operations. Revenue for the quarter was 12.31 million USD, up nominally from the prior quarter on a QoQ basis but down meaningfully year over year, reflecting the company’s transition to a primarily immuno-oncology (IO) growth engine anchored by LOQTORZI and an advancing pipeline. LOQTORZI net sales rose 61% YoY, underscoring strong uptake in the nascent launch, but the sequential drop to 11.8 million USD in Q1 2026 versus Q4 2025’s 12.4 million USD highlights seasonality and external disruptions (severe winter weather) that temporarily pressured physician ordering and patient cycles. Management maintained a constructive longer‑term revenue trajectory for LOQTORZI, with explicit quarterly targets of approximately 15 million USD in 2026, 30–35 million USD in 2027, and 44 million USD per quarter in 2028 (about 175 million USD annualized). The company also reiterated a multi‑year R&D and development path around casdozokitug (HCC via CATALYST program) and tagmokitug (CCR8 antibody) with multiple cohorts and midyear readouts planned. Cash and liquidity were reinforced by a follow‑on equity offering that generated net proceeds of about 54 million USD, bringing total cash, cash equivalents and investments to 167 million USD at quarter end, and supporting funding through key data readouts in 2026–2027. While the near‑term GAAP earnings remain negative, the setup presents a clear path toward leveraged IO growth and a diversified and expanding clinical pipeline that could alter the risk–reward profile for investors over the next 12–24 months.